Search | Clinical Trials Finder

Conditions: Healthy
Interventions: PF-07314470, Placebo for PF-07314470; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: PF-06743649, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Osteoarthritis
Interventions: Investigational Medical Product (IMP) administered in parent study; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 51
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 36 more

Conditions: Healthy
Interventions: HFB30132A, Placebo; Drug · Other
Lead sponsor: HiFiBiO Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: XXB750 in Healthy Participants
Interventions: XXB750, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Cypress, California

Conditions: Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
Interventions: ANK-700, Placebo; Drug
Lead sponsor: Anokion SA; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 15
States / cities: Cullman, Alabama • Phoenix, Arizona • Aurora, Colorado + 12 more

Conditions: Healthy Participants
Interventions: SAD IMG-004 30mg, SAD IMG-004 100mg, SAD IMG-004 200mg, SAD IMG-004 400mg, SAD IMG-004 600mg, SAD Placebo 30mg, SAD Placebo 100mg, SAD Placebo 200mg, SAD Placebo 400mg, SAD Placebo 600mg, MAD IMG-004 50mg, MAD Placebo 50mg, MAD IMG-004 150mg, MAD Placebo 150mg, MAD IMG-004 300mg, MAD Placebo 300mg, FE IMG-004 150mg; Drug
Lead sponsor: Inmagene LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy Volunteers
Interventions: Fasinumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Glendale, California

Conditions: Hereditary Angioedema
Interventions: Donidalorsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Scottsdale, Arizona • San Diego, California • Santa Monica, California + 12 more

Conditions: TB Multi-drug Resistant
Interventions: SQ109, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: LY3839840, Placebo, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Anaheim, California • Madison, Wisconsin

Conditions: Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Interventions: ALV-100, Placebo; Drug
Lead sponsor: Alveus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Miami, Florida • Columbus, Ohio • San Antonio, Texas

Conditions: Dyslipidaemias
Interventions: an undetermined dose of GSK1292263, ascending dose of GSK1292263; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Ulcerative Colitis
Interventions: Filgotinib, PTM filgotinib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 61
States / cities: Dothan, Alabama • Scottsdale, Arizona • Long Beach, California + 53 more

Conditions: Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
Interventions: Antizol, Placebo, Ethanol; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: HIV Infections
Interventions: KD-247, Physiological saline; Drug
Lead sponsor: The Chemo-Sero-Therapeutic Research Institute; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 15
States / cities: Beverly Hills, California • Burbank, California • Los Angeles, California + 12 more

Conditions: Healthy Volunteers
Interventions: REGN2222(SAR438584), placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas

Conditions: Glaucoma
Interventions: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops; Drug · Procedure · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Dothan, Alabama

Conditions: Anthrax
Interventions: Px563L, RPA563, or placebo; Biological
Lead sponsor: Pfenex, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hereditary Angioedema (HAE)
Interventions: Recombinant human C1 esterase inhibitor, Placebo, SHP623; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Gastroparesis
Interventions: CIN-102 Dose 1, CIN-102 Dose 2, CIN-102 Dose 3, Placebo; Drug
Lead sponsor: CinDome Pharma, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 19
States / cities: Chula Vista, California • Jacksonville, Florida • Miami, Florida + 15 more

Conditions: Healthy Volunteers
Interventions: NUV001 active cohort 1, NUV001 active cohort 2, NUV001 active cohort 3, NUV001 active cohort 4, NUV001 placebo cohort 1, NUV001 placebo cohort 2, NUV001 placebo cohort 3, NUV001 placebo cohort 4; Drug
Lead sponsor: Nuvamid SA; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Thromboangiitis Obliterans (Buerger's Disease)
Interventions: ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g), Placebo; Biological · Other
Lead sponsor: Antidote Therapeutics, Inc; Industry
Eligibility: 23 Years to 59 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults

A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649

Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement

Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults

Safety, Tolerability, and Pharmacokinetics of XXB750 in Healthy Participants

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

Study to Evaluate IMG-004 in Healthy Participants

Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

Dose Escalation Study of SQ109 in Healthy Adult Volunteers

A First-In-Human Study of LY3839840 in Healthy Participants

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis

Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism

A Study of Anti-HIV Monoclonal Antibody KD-247

Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects

Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers